The DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index.
A systematic review of the role of bisphosphonates in metastatic disease
Open accessAbstract
OBJECTIVES: To identify evidence for the role of bisphosphonates in malignancy for the treatment of hypercalcaemia, prevention of skeletal morbidity and use in the adjuvant setting. To perform an economic review of current literature and model the cost effectiveness of bisphosphonates in the treatment of hypercalcaemia and prevention of skeletal morbidity. DATA SOURCES: Electronic databases (1966-June 2001). Cochrane register. Pharmaceutical companies. Experts in the field. Handsearching of abstracts and leading oncology journals (1999-2001). REVIEW METHODS: Two independent reviewers assessed studies for inclusion, according to predetermined criteria, and extracted relevant data. Overall event rates were pooled in a meta-analysis, odds ratios (OR) were given with 95% confidence intervals (CI). Where data could not be combined, studies were reported individually and proportions compared using chi-squared analysis. Cost and cost-effectiveness were assessed by a decision analytic model comparing different bisphosphonate regimens for the treatment of hypercalcaemia; Markov models were employed to evaluate the use of bisphosphonates to prevent skeletal-related events (SRE) in patients with breast cancer and multiple myeloma. RESULTS: For acute hypercalcaemia of malignancy, bisphosphonates normalised serum calcium in >70% of patients within 2-6 days. Pamidronate was more effective than control, etidronate, mithramycin and low-dose clodronate, but equal to high dose clodronate, in achieving normocalcaemia. Pamidronate prolongs (doubles) the median time to relapse compared with clodronate or etidronate. For prevention of skeletal morbidity, bisphosphonates compared with placebo, significantly reduced the OR for fractures (OR [95% CI], vertebral, 0.69 [0.57-0.84], non-vertebral, 0.65 [0.54-0.79], combined, 0.65 [0.55-0.78]) radiotherapy 0.67 [0.57-0.79] and hypercalcaemia 0.54 [0.36-0.81] but not orthopaedic surgery 0.70 [0.46-1.05] or spinal cord compression 0.71 [0.47-1.08]. However, reduction in orthopaedic surgery was significant in studies that lasted over a year 0.59 [0.39-0.88]. Bisphosphonates significantly increased the time to first SRE but did not affect survival. Subanalyses were performed for disease groups, drugs and route of administration. Most evidence supports the use of intravenous aminobisphosphonates. For adjuvant use of bisphosphonates, Clodronate, given to patients with primary operable breast cancer and no metastatic disease, significantly reduced the number of patients developing bone metastases. This benefit was not maintained once regular administration had been discontinued. Two trials reported significant survival advantages in the treated groups. Bisphosphonates reduce the number of bone metastases in patients with both early and advanced breast cancer. Bisphosphonates are well tolerated with a low incidence of side-effects. Economic modelling showed that for acute hypercalcaemia, drugs with the longest cumulative duration of normocalcaemia were most cost-effective. Zoledronate 4 mg was the most costly, but most cost-effective treatment. For skeletal morbidity, Markov models estimated that the overall cost of bisphosphonate therapy to prevent an SRE was GBP250 and GBP1500 per event for patients with breast cancer and multiple myeloma, respectively. Bisphosphonate treatment is sometimes cost-saving in breast cancer patients where fractures are prevented. CONCLUSIONS: High dose aminobisphosphonates are most effective for the treatment of acute hypercalcaemia and delay time to relapse. Bisphosphonates significantly reduce SREs and delay the time to first SRE in patients with bony metastatic disease but do not affect survival. Benefit is demonstrated after administration for at least 6-12 months. The greatest body of evidence supports the use of intravenous aminobisphosphonates. Further evidence is required to support use in the adjuvant setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The distribution of secondary growths in cancer of the breast.
Paget, S. (1889) · The Lancet · doi:10.1016/s0140-6736(00)49915-0 · Cited by 5,277
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.
Bucay, N., Sarosi, I., Dunstan, C. R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H. L., Xu, W., Lacey, D. L., et al. (1998) · Genes & Development · doi:10.1101/gad.12.9.1260 · Cited by 2,483
Recommendations of the Panel on Cost-Effectiveness in Health and Medicine
Weinstein, M. C. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540150055031 · Cited by 2,455
Systematic Reviews: Identifying relevant studies for systematic reviews
Dickersin, K., Scherer, R., & Lefebvre, C. (1994) · BMJ · doi:10.1136/bmj.309.6964.1286 · Cited by 2,256
Saad, F., Gleason, D. M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., Chin, J. L., Vinholes, J. J., Goas, J. A., & Chen, B. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.19.1458 · Cited by 1,656
Skeletal complications of malignancy
Coleman, R. E. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19971015)80:8+<1588::aid-cncr9>3.0.co;2-g · Cited by 1,502
Luckman, S. P., Hughes, D. E., Coxon, F. P., Russell, R. G. G., & Dr. Rogers, M. J. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.4.581 · Cited by 1,176
The clinical course of bone metastases from breast cancer
Coleman, R., & Rubens, R. (1987) · British Journal of Cancer · doi:10.1038/bjc.1987.13 · Cited by 1,084
Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma
Berenson, J. R., Lichtenstein, A., Porter, L., Dimopoulos, M. A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M. J., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602223340802 · Cited by 1,081
Hortobagyi, G. N., Theriault, R. L., Porter, L., Blayney, D., Lipton, A., Sinoff, C., Wheeler, H., Simeone, J. F., Seaman, J., Knight, R. D., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612123352401 · Cited by 1,026
The Markov process in medical prognosis
Beck, J. R., & Pauker, S. G. (1983) · Medical Decision Making · doi:10.1177/0272989x8300300403 · Cited by 957
Interpretation of Serum Calcium in Patients with Abnormal Serum Proteins
Payne, R. B., Little, A. J., Williams, R. B., & Milner, J. R. (1973) · BMJ · doi:10.1136/bmj.4.5893.643 · Cited by 945
Dunford, J. E., Thompson, K., Coxon, F. P., Luckman, S. P., Hahn, F. M., Poulter, C. D., Ebetino, F. H., & Rogers, M. J. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38786-5 · Cited by 900
Rosen, L. S., Gordon, D., Kaminski, M., Howell, A., Belch, A. R., Mackey, J. R., Apffelstaedt, J., Hussein, M., Coleman, R. E., Reitsma, D. J., et al. (2001) · PubMed · Cited by 896
Major, P., Lortholary, A., Hon, J., Abdi, E., Mills, G., Menssen, H. D., Yunus, F., Bell, R., Body, J., Quebe-Fehling, E., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.558 · Cited by 858
Reduction in New Metastases in Breast Cancer with Adjuvant Clodronate Treatment
Diel, I. J., Solomayer, E.-F., Costa, S. D., Gollan, C., Goerner, R., Wallwiener, D., Kaufmann, M., & Bastert, G. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808063390601 · Cited by 809
Development of Matrix Metalloproteinase Inhibitors in Cancer Therapy
Hidalgo, M., & Eckhardt, S. G. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.3.178 · Cited by 798
Fleisch, H., Graham, R., Russell, G., & Francis, M. D. (1969) · Science · doi:10.1126/science.165.3899.1262 · Cited by 758
Lipton, A., Theriault, R. L., Hortobagyi, G. N., Simeone, J., Knight, R. D., Mellars, K., Reitsma, D. J., Heffernan, M., & Seaman, J. J. (2000) · Cancer · doi:10.1002/(sici)1097-0142(20000301)88:5<1082::aid-cncr20>3.0.co;2-z · Cited by 665
Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Cited by 650
Berenson, J. R., Lichtenstein, A., Porter, L., Dimopoulos, M. A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.593 · Cited by 648
Hortobagyi, G. N., Theriault, R. L., Lipton, A., Porter, L., Blayney, D., Sinoff, C., Wheeler, H., Simeone, J. F., Seaman, J. J., Knight, R. D., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.6.2038 · Cited by 631
Theriault, R. L., Lipton, A., Hortobagyi, G. N., Leff, R., Glück, S., Stewart, J. F., Costello, S., Kennedy, I., Simeone, J., Seaman, J. J., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.3.846 · Cited by 604
Boissier, S., Ferreras, M., Peyruchaud, O., Magnetto, S., Ebetino, F. H., Colombel, M. C., Delmas, P. D., Delaissé, J., & Clézardin, P. (2000) · PubMed · Cited by 573
Paterson, A. H., Powles, T. J., Kanis, J. A., McCloskey, E., Hanson, J., & Ashley, S. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.1.59 · Cited by 557
Bisphosphonates in Bone Disease: From the Laboratory to the Patient
Fleisch, H. A. (1995) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · Cited by 472
The inhibition of calcium hydroxyapatite crystal growth by polyphosphonates and polyphosphates
Francis, M. D. (1969) · Calcified Tissue Research · doi:10.1007/bf02058658 · Cited by 399
Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma
Lahtinen, R., Laakso, M., Palva, I., Elomaa, I., & Virkkunen, P. (1992) · The Lancet · doi:10.1016/0140-6736(92)93075-x · Cited by 385
American Society of Clinical Oncology Guideline on the Role of Bisphosphonates in Breast Cancer
Hillner, B. E., Ingle, J. N., Berenson, J. R., Janjan, N. A., Albain, K. S., Lipton, A., Yee, G., Biermann, J. S., Chlebowski, R. T., Pfister, D. G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.6.1378 · Cited by 383
Randomized, Placebo-Controlled Trial of Clodronate in Patients With Primary Operable Breast Cancer
Powles, T., Paterson, S., Kanis, J. A., McCloskey, E., Ashley, S., Tidy, A., Rosenqvist, K., Smith, I., Ottestad, L., Legault, S., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.080 · Cited by 377
Carlin, B. I., & Andriole, G. L. (2000) · Cancer · doi:10.1002/1097-0142(20000615)88:12+<2989::aid-cncr14>3.0.co;2-q · Cited by 363
Dr. Coxon, F. P., Helfrich, M. H., Van't Hof, R., Sebti, S., Ralston, S. H., Hamilton, A., & Rogers, M. J. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.8.1467 · Cited by 361
Isolation from urine of pyrophosphate, a calcification inhibitor
Fleisch, H., & Bisaz, S. (1962) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1962.203.4.671 · Cited by 349
Saarto, T., Blomqvist, C., Virkkunen, P., & Elomaa, I. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.1.10 · Cited by 341
Bisphosphonate treatment inhibits the growth of prostate cancer cells.
Lee, M. V., Fong, E. D. M., Singer, F. R., & Guenette, R. S. (2001) · PubMed · Cited by 338
Parfitt, A. M., Mundy, G. R., Roodman, G. D., Hughes, D. E., & Boyce, B. F. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650110203 · Cited by 336
Molecular mechanisms of osteolytic bone metastases
Guise, T. A. (2000) · Cancer · doi:10.1002/1097-0142(20000615)88:12+<2892::aid-cncr2>3.0.co;2-y · Cited by 331
Fleisch, H. A., Russell, R. G. G., Bisaz, S., Mühlbauer, R. C., & Williams, D. A. (1970) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1970.tb00591.x · Cited by 325
A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma
McCloskey, MacLennan, Drayson, Chapman, Dunn, Kanis, & Adults, F. T. M. W. P. O. L. I. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00567.x · Cited by 314
Role of cytokines in bone resorption
Manolagas, S. C. (1995) · Bone · doi:10.1016/8756-3282(95)00180-l · Cited by 312
Biology of Osteoclast Activation in Cancer
Roodman, G. D. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.15.3562 · Cited by 306
NICE: faster access to modern treatments? Analysis of guidance on health technologies
Raftery, J. (2001) · BMJ · doi:10.1136/bmj.323.7324.1300 · Cited by 299
Symptom management in advanced cancer
Twycross, R., Wilcock, A., & Toller, C. S. (1995) · Medical Entomology and Zoology · Cited by 291
The Cost of Treating Osteoporotic Fractures in the United Kingdom Female Population
Dolan, P., & Torgerson, D. J. (1998) · Osteoporosis International · doi:10.1007/s001980050107 · Cited by 290
The pharmacology of bisphosphonates and new insights into their mechanisms of action
Russell, R. G. G., Rogers, M. J., Frith, J. C., Luckman, S. P., Coxon, F. P., Benford, H. L., Croucher, P. I., Shipman, C., & Fleisch, H. A. (1999) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650140212 · Cited by 279
Conte, P. F., Latreille, J., Mauriac, L., Calabresi, F., Santos, R., Campos, D., Bonneterre, J., Francini, G., & Ford, J. M. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.9.2552 · Cited by 268
Saarto, T., Blomqvist, C., Välimäki, M., Mäkelä, P., Sarna, S., & Elomaa, I. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1341 · Cited by 265
BMA (2003) · Cited by 245
Molecular mechanisms of action of bisphosphonates
Rogers, M. J., Frith, J. C., Luckman, S. P., Coxon, F. P., Benford, H. L., M̈onkk̈onen, J., Auriola, S., Chilton, K. M., & Russell, R. G. G. (1999) · Bone · doi:10.1016/s8756-3282(99)00070-8 · Cited by 237
Direct resorption of bone by human breast cancer cells in vitro
EILON, G., & MUNDY, G. R. (1978) · Nature · doi:10.1038/276726a0 · Cited by 235
Nussbaum, S. R., Younger, J., Vandepol, C. J., Gagel, R. F., Zubler, M. A., Chapman, R., Henderson, I. C., & Mallette, L. E. (1993) · The American Journal of Medicine · doi:10.1016/0002-9343(93)90282-t · Cited by 228
Clodronate decreases the frequency of skeletal metastases in women with breast cancer
Kanis, J. A., Powles, T., Paterson, A. H. G., McCloskey, E. V., & Ashley, S. (1996) · Bone · doi:10.1016/s8756-3282(96)00285-2 · Cited by 224
Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases.
Elomaa, I., Blomqvist, C., Gröhn, P., Porkka, L., Kairento, A.-L., Selander, K., Lamberg-Allardt, C., & Holmström, T. (1983) · The Lancet · doi:10.1016/s0140-6736(83)92755-1 · Cited by 209
Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma
Yoneda, T., Michigami, T., Yi, B., Williams, P. J., Niewolna, M., & Hiraga, T. (2000) · Cancer · Cited by 206
van Holten-Verzantvoort, A. T., Bijvoet, O. L. M., Hermans, J., Harinck, H. I. J., Elte, J. W. F., Beex, L. V. A. M., Cleton, F. J., Kroon, H. M., Vermey, P., Neijt, J. P., et al. (1987) · The Lancet · doi:10.1016/s0140-6736(87)92555-4 · Cited by 202
Fulfaro, F., Casuccio, A., Ticozzi, C., & Ripamonti, C. (1998) · Pain · doi:10.1016/s0304-3959(98)00135-3 · Cited by 196
Palliative pamidronate treatment in patients with bone metastases from breast cancer.
van Holten-Verzantvoort, A. T., Kroon, H. M., Bijvoet, O. L., Cleton, F. J., Beex, L. V., Blijham, G., Hermans, J., Neijt, J. P., Papapoulos, S. E., & Sleeboom, H. P. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.491 · Cited by 196
FOCAL OSTEOMALACIA DUE TO LOW-DOSE DIPHOSPHONATE THERAPY IN PAGET'S DISEASE
Boyce, B. F., Fogelman, I., Ralston, S., Smith, L., Johnston, E., & Boyle, I. T. (1984) · The Lancet · doi:10.1016/s0140-6736(84)92272-4 · Cited by 196
COMPARISON OF THREE INTRAVENOUS BISPHOSPHONATES IN CANCER-ASSOCIATED HYPERCALCAEMIA
Ralston, S., Patel, U., Fraser, W., Gallacher, S., Dryburgh, F., Cowan, R., & Boyle, I. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91791-1 · Cited by 195
Ralston, S. H., Dryburgh, F. J., Cowan, R. A., Gardner, M. D., Jenkins, A. S., & Boyle, I. T. (1985) · The Lancet · doi:10.1016/s0140-6736(85)90848-7 · Cited by 192
Recommendations of the Panel on Cost-Effectiveness in Health and Medicine
WEINSTEIN, M. C., SIEGEL, J. E., GOLD, M. R., KAMLET, M. S., & RUSSELL, L. B. (1997) · Survey of Anesthesiology · doi:10.1097/00132586-199712000-00019 · Cited by 191
Effect of daily etidronate on the osteolysis of multiple myeloma.
Belch, A. R., Bergsagel, D. E., Wilson, K., O'Reilly, S., Wilson, J., Sutton, D., Pater, J., Johnston, D., & Zee, B. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.8.1397 · Cited by 178
The Economic Cost of Hip Fractures in Community‐Dwelling Older Adults: A Prospective Study
Brainsky, A., Glick, H., Lydick, E., MD, R. E., Fox, K. M., Hawkes, W., Kashner, T. M., Zimmerman, S. I., & Magaziner, J. (1997) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1997.tb00941.x · Cited by 176
Oral clodronate in breast cancer patients with bone metastases: a randomized study
Kristensen, B., Ejlertsen, B., Groenvold, M., Hein, S., Loft, H., & Mouridsen, H. T. (1999) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1999.00507.x · Cited by 176
Comparative Tolerability of Drug Therapies for Hypercalcaemia of Malignancy
Zojer, N., Keck, A. V., & Pecherstorfer, M. (1999) · Drug Safety · doi:10.2165/00002018-199921050-00004 · Cited by 167
Comparative study of available medical therapy for hypercalcemia of malignancy
Mundy, G. R., Wilkinson, R., & Heath, D. A. (1983) · The American Journal of Medicine · doi:10.1016/0002-9343(83)90961-0 · Cited by 163
Vinholes, J. J. F., Prakash Purohit, O., Abbey, M. E., Eastell, R., & Coleman, R. E. (1997) · Annals of Oncology · doi:10.1023/a:1008238422151 · Cited by 163
Costs Induced by Hip Fractures: A Prospective Controlled Study in Belgium
Autier, P., Haentjens, P., Bentin, J., Baillon, J. M., Grivegnée, A. R., Closon, M. C., & Boonen, S. (2000) · Osteoporosis International · doi:10.1007/s001980070102 · Cited by 161
Biochemical markers and skeletal metastases
Demers, L. M., Costa, L., & Lipton, A. (2000) · Cancer · doi:10.1002/1097-0142(20000615)88:12+<2919::aid-cncr7>3.0.co;2-z · Cited by 161
Powles, T. J., Ashley, S., Tidy, V. A., Nevantaus, A., McCloskey, E., Kanis, J. A., Paterson, A. H. G., & Rosenqvist, K. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.9.704 · Cited by 159
Warrell, R. P., ISRAEL, R., FRISONE, M., SNYDER, T., GAYNOR, J. J., & BOCKMAN, R. S. (1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-5-669 · Cited by 157
Gucalp, R. A., Ritch, P. S., Wiernik, P. H., Sarma, P. R., Keller, A. M., Richman, S. P., Tauer, K. W., Neidhart, J. A., Mallette, L. E., & Siegel, R. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.1.134 · Cited by 150
Payne, R. B., Carver, M. E., & Morgan, D. B. (1979) · Journal of Clinical Pathology · doi:10.1136/jcp.32.1.56 · Cited by 143
Influence of pyrophosphate on the transformation of amorphous to crystalline calcium phosphate
Fleisch, H. A., Russell, R. G. G., Bisaz, S., Termine, J. D., & Posner, A. S. (1968) · Calcified Tissue International · doi:10.1007/bf02279193 · Cited by 143
Markers of bone resorption in patients treated with pamidronate
Lipton, A., Demers, L., Curley, E., Chinchilli, V. M., Gaydos, L. J., Hortobágyi, G. N., Theriault, R. L., Clemens, D., Costa, L., Seaman, J. J., et al. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00277-9 · Cited by 139
Vehmanen, L., Saarto, T., Elomaa, I., Mäkelä, P. M., Välimäki, M. J., & BLOMQVIST, C. P. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00317-3 · Cited by 133
Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia
Ralston, S. H., Thiébaud, D., Herrmann, Z., Steinhauer, E., Thurlimann, B. J. K., Walls, J., Lichinitser, M., Rizzoll, R., Hagberg, H., Huss, H., et al. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.48 · Cited by 129
Effects of disodium dichloromethylene diphosphonate on hypercalcemia produced by bone metastases.
Chapuy, M. C., Meunier, P. J., Alexandre, C. M., & Vignon, E. P. (1980) · Journal of Clinical Investigation · doi:10.1172/jci109780 · Cited by 125
Pecherstorfer, M., Herrmann, Z., Body, J., Manegold, C., Degardin, M., Clemens, M., Thurlimann, B. J. K., Tubiana-Hulin, M., Steinhauer, E. U., Eijkeren, M. V., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.1.268 · Cited by 124
Delmas, P. D., CHARHON, S. A., Chapuy, M. C., Vignon, E. P., Briançon, D., Edouard, C. M., & Meunier, P. J. (1982) · Metabolic Bone Disease and Related Research · doi:10.1016/0221-8747(82)90013-3 · Cited by 124
Autzen, P., Robson, C. N., Bjartell, A. S., Malcolm, A. J., Johnson, M. I., Neal, D. E., & Hamdy, F. C. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.658 · Cited by 123
Mundy, G. R., Yoneda, T., & Hiraga, T. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90263-5 · Cited by 121
A double-blind, crossover trial of intravenous clodronate in metastatic bone pain
Ernst, D. S., MacDonald, R. N., Paterson, A. H. G., Jensen, J., Brasher, P. M. A., & Bruera, E. D. (1992) · Journal of Pain and Symptom Management · doi:10.1016/0885-3924(92)90101-m · Cited by 119
Clodronate kinetics and bioavailability
Yakatan, G. J., Poynor, W. J., Talbert, R. L., Floyd, B. F., Slough, C. L., Ampulski, R. S., & Benedict, J. J. (1982) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1982.51 · Cited by 117
Diel, I., Solomayer, E., Seibel, M. J., Pfeilschifter, J., Maisenbacher, H. W., Gollan, C., Pecherstorfer, M., Conradi, R., Kehr, G., Boehm, E., et al. (1999) · PubMed · Cited by 117
Hultborn, R., Gundersen, S., Rydén, S., Holmberg, E. C., Carstensen, J. M., Wallgren, U.-B., Killany, S., Andreassen, L., Carlsson, G. U., Fahl, N., et al. (1999) · PubMed · Cited by 115
Brincker, H., Westin, J., Abildgaard, N., Gimsing, P., Turesson, I., Hedenus, M., Ford, J., & Kandra, A. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00695.x · Cited by 114
Bone and cancer: Pathophysiology and treatment of metastases
Kanis, J. А. (1995) · Bone · doi:10.1016/8756-3282(95)00194-i · Cited by 108
Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study.
Robertson, A. G., Reed, N. S., & Ralston, S. H. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.9.2427 · Cited by 99
Coleman, R. E., Purohit, O. P., Black, C., Vinholes, J., Schlosser, K., Huss, H., Quinn, K. J., & Kanis, J. A. (1999) · Annals of Oncology · doi:10.1023/a:1008386501738 · Cited by 95
Aggregation of hydroxyapatite crystals
Hansen, N. M., Felix, R., Bisaz, S., & Fleisch, H. A. (1976) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/0304-4165(76)90150-1 · Cited by 95
Singer, F. R. (1991) · Archives of Internal Medicine · doi:10.1001/archinte.1991.00400030039007 · Cited by 93
van Holten-Verzantvoort, A. T. M., Zwinderman, A. H., Aaronson, N. K., Hermans, J., van Emmerik, B., van Dam, F. S. A. M., van den Bos, B., Bijvoet, O. L. M., & Cleton, F. J. (1991) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(91)90212-v · Cited by 92
Safety and Efficacy of Bisphosphonates Beyond 24 Months in Cancer Patients
Ali, S. M., Esteva, F. J., Hortobágyi, G. N., Harvey, H., Seaman, J. J., Knight, R., Costa, L., & Lipton, A. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3434 · Cited by 91
Multiple ulcerative esophagitis caused by alendronate.
Maconi, G., & Bianchi Porro, G. (1995) · PubMed · Cited by 90
Disaggregation of hydroxyapatite crystals
Bisaz, S., Felix, R., Hansen, N. M., & Fleisch, H. A. (1976) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/0304-4165(76)90151-3 · Cited by 81
Pathophysiologic interactions in skeletal metastasis
Orr, F. W., Lee, J., Duivenvoorden, W., & Singh, G. (2000) · Cancer · doi:10.1002/1097-0142(20000615)88:12+<2912::aid-cncr6>3.0.co;2-8 · Cited by 79
Hall, D. G., & Stoica, G. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090211 · Cited by 74
Effects of dichloromethylene diphosphonate in women with breast carcinoma metastatic to the skeleton
Siris, E. S., Hyman, G. A., & Canfield, R. E. (1983) · The American Journal of Medicine · doi:10.1016/0002-9343(83)90958-0 · Cited by 73
Kim, R. H., & Sodek, J. (1999) · PubMed · Cited by 72
Castel, L. D., Bajwa, K., Markle, J. P., Timbie, J. W., Zacker, C., & Schulman, K. A. (2001) · Supportive Care in Cancer · doi:10.1007/s005200100249 · Cited by 72
Metabolic effects of pamidronate in patients with metastatic bone disease
Vinholes, J., Guo, C., Purohit, O., Eastell, R., & Coleman, R. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.210 · Cited by 71
Gucalp, R. A. (1994) · Archives of Internal Medicine · doi:10.1001/archinte.1994.00420170079008 · Cited by 71
Terpos, E., Palermos, J., Tsionos, K., Anargyrou, K., Viniou, N. A., Papasavas, P., Meletis, J., & Yataganas, X. (2000) · European Journal Of Haematology · doi:10.1034/j.1600-0609.2000.065005331.x · Cited by 69
Merlini, G., Parrinello, G. A., Piccinini, L., Crema, F., Fiorentini, M., Riccardi, A., Pavesi, F., Novazzi, F., Silingardi, V., & Ascari, E. (1990) · Hematological Oncology · doi:10.1002/hon.2900080104 · Cited by 67
Abildgaard, N., Rungby, J., Glerup, H., Brixen, K., Kassem, M., Brincker, H., Heickendorff, L., Eriksen, E. F., & Nielsen, J. L. (1998) · European Journal of Haematology · doi:10.1111/j.1600-0609.1998.tb01073.x · Cited by 64
Morton, A. R., Cantrill, J. A., Craig, A. E., Howell, A., Davies, M., & Anderson, D. C. (1988) · BMJ · doi:10.1136/bmj.296.6625.811 · Cited by 62
Parathyroid hormone-related protein (PTHrP) and hypercalcaemia
Grill, V., Rankin, W. A., & Martin, T. J. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(97)10130-7 · Cited by 62
Coleman, R., Purohit, O. P., Vinholes, J., & Zekri, J. (1997) · Cancer · Cited by 62
Predictive Value of Derived Calcium Figures Based on the Measurement of Ionised Calcium
Gardner, M. D., Dryburgh, F. J., Fyffe, J. A., et al. (1981) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/000456328101800210 · Cited by 59
Walls, J., RATCLIFFE, W. A., Howell, A., & Bundred, N. J. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.270 · Cited by 58
Krempien, B., Wingen, F.-J., Eichmann, T., Müller, M., & Schmähl, D. (2009) · Oncology · doi:10.1159/000226528 · Cited by 58
Lipton, A., Glover, D. J., Harvey, H. A., Grabelsky, S. A., Zelenakas, K., Macerata, R. S., & Seaman, J. A. (1994) · PubMed · Cited by 57
Zhang, Y., Fujita, N., Oh‐hara, T., Morinaga, Y., Nakagawa, T., Yamada, M., & Tsuruo, T. (1998) · Oncogene · doi:10.1038/sj.onc.1201581 · Cited by 56
Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia.
Nussbaum, S. R., Warrell, R. P., Rude, R. K., Glusman, J. E., Bilezikian, J. P., Stewart, A. F., Stepanavage, M., Sacco, J. F., Averbuch, S. D., & Gertz, B. J. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.8.1618 · Cited by 54
Efficiency of Searching the Grey Literature in Palliative Care
Cook, A., Finlay, I. G., Edwards, A., Hood, K., Higginson, I. J., Goodwin, D. M., Normand, C. E. M., & Douglas, H.-R. (2001) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(01)00315-3 · Cited by 54
Self-citationHeim, M., Clemens, M. R., Queißer, W., Pecherstorfer, M., Boewer, C., Herold, M. J., Franke, A., Herrmann, Z., Loose, R., & Edler, L. (2009) · Onkologie · doi:10.1159/000218633 · Cited by 52
Thurlimann, B. J. K., Waldburger, R., Senn, H.-J., & Thiébaud, D. (1992) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058287 · Cited by 51
Saarto, T., Vehmanen, L., Elomaa, I., Välimäki, M., Mäkelä, P. M., & BLOMQVIST, C. P. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1729 · Cited by 50
Etidronate disodium in the management of malignancy-related hypercalcemia
Hasling, C., Charles, P., & Mosekilde, L. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90487-6 · Cited by 50
Body, J. J., Magritte, A., Seraj, F., Sculier, J., & Borkowski, A. J. (1989) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650040617 · Cited by 48
Clodronate for osteolytic metastases due to breast cancer.
Elomaa, I., BLOMQVIST, C. P., Porkka, L., Holmström, T., Taube, T., Lamberg-Allardt, C. J. E., & Borgström, G. H. (1988) · PubMed · Cited by 48
Attardo-Parrinello, G. (1987) · Archives of Internal Medicine · doi:10.1001/archinte.1987.00370090105018 · Cited by 44
Ralston, S. H., Alzaid, A., Gallacher, S., Gardner, M. D., Cowan, R. A., & Boyle, I. T. (1988) · QJM · doi:10.1093/oxfordjournals.qjmed.a068248 · Cited by 44
Multiple myeloma: effect of daily dichloromethylene bisphosphonate on skeletal complications
Clemens, M., Fessele, K., & Heim, M. (1993) · Annals of Hematology · doi:10.1007/bf01697625 · Cited by 42
The potential role of bisphosphonates as adjuvant therapy in the prevention of bone metastases
Paterson, A. H. G. (2000) · Cancer · doi:10.1002/1097-0142(20000615)88:12+<3038::aid-cncr21>3.0.co;2-v · Cited by 41
McCloskey, E. V., Guest, J. F., & Kanis, J. A. (2001) · Drugs · doi:10.2165/00003495-200161090-00003 · Cited by 41
Coleman, R. E., Houston, S. J., Purohit, O. P., Rubens, R. D., Kandra, A., & Ford, J. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(97)10155-1 · Cited by 41
Pamidronate treatment in patients with malignant osteolytic bone disease and pain
Koeberle, D., Bacchus, L., Thuerlimann, B., & Senn, H.-J. (1999) · Supportive Care in Cancer · doi:10.1007/s005200050218 · Cited by 40
Daragon, A., Humez, C., Michot, C., Loët, X. L., Grosbois, B., Pouyol, F., EULLER-ZIEGLER, L., Azaïs, I., Jf, B., & Ménard, J.-F. (1993) · PubMed · Cited by 38
The calcium fractions of normal serum
Raman, A. A. A. (1971) · Clinical Biochemistry · doi:10.1016/s0009-9120(71)91175-1 · Cited by 36
Hultborn, R., Gundersen, S., Rydén, S., et al. (1996) · Acta Oncologica · doi:10.3109/02841869609083974 · Cited by 33
Sawyer, N., Newstead, C. G., Drummond, A., & Cunningham, J. (1990) · Bone and Mineral · doi:10.1016/0169-6009(90)90078-t · Cited by 32
Bockman, R. S. (1980) · Clinics in Endocrinology and Metabolism · doi:10.1016/s0300-595x(80)80036-3 · Cited by 30
Davis, J. R., & Heath, D. (1989) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1989.tb05426.x · Cited by 25
Zysset, E., Ammann, P., Jenzer, A., Gertz, B. J., Portmann, L., Rizzoli, R., Jaquet-Müller, F., Pryor-Tillotson, S., Bonjour, J. ‐., & Burckhardt, P. (1992) · Bone and Mineral · doi:10.1016/0169-6009(92)90810-z · Cited by 24
Survival in breast cancer patients after the first episode of hypercalcaemia
Kristensen, Ejlertsen, Mouridsen, & Loft (1998) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1998.00355.x · Cited by 22
Wislöff, F., Gulbrandsen, N., & Nord, E. (1999) · PharmacoEconomics · doi:10.2165/00019053-199916040-00002 · Cited by 21
Maintenance Etidronate in the Prevention of Malignancy-Associated Hypercalcemia
Schiller, J. H. (1987) · Archives of Internal Medicine · doi:10.1001/archinte.147.5.963 · Cited by 20
Gessner, U., Koeberle, D., Thuerlimann, B., Bacchus, L., & Horisberger, B. (2000) · Supportive Care in Cancer · doi:10.1007/s005200050025 · Cited by 20
Cleton, F. J., van Holten-Verzantvoort, A. T., & Bijvoet, O. L. M. (1989) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-83668-8_7 · Cited by 20
Skeletal Response to Clodronate in Prostate Cancer with Bone Metastases
Fernández-Conde, M., Alcóver, J., Aaron, J. E., Ordï, J., & Carretero, P. (1997) · American Journal of Clinical Oncology · doi:10.1097/00000421-199710000-00007 · Cited by 19
Morphological Findings in Bone Metastasis, Tumorosteopathy and Antiosteolytic Therapy
Krempien, B. (1994) · Springer eBooks · doi:10.1007/978-3-642-78596-2_6 · Cited by 17
Hasling, C., Charles, P., & Mosekilde, L. (1986) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1986.tb01019.x · Cited by 17
Disodium Pamidronate Versus Mithramycin in the Management of Tumour-Associated Hypercalcemia
Østenstad, B., & Andersen, O. K. (1992) · Acta Oncologica · doi:10.3109/02841869209089719 · Cited by 17
Review article : Hypercalcaemia of malignancy
Heath, D. (1989) · Palliative Medicine · doi:10.1177/026921638900300102 · Cited by 14
Kraj, M. A., Pogłód, R., Pawlikowski, J., Maj, S., & Nasiłowska, B. (2000) · PubMed · Cited by 14
The Role of Bisphosphonates in Malignant Bone Pain: A Review
Pereira, J. L., Mancini, I. L., & Walker, P. (1998) · Journal of Palliative Care · doi:10.1177/082585979801400205 · Cited by 12
Hormonal Factors Which Regulate Bone Resorption
Mundy, G. R. (1993) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-77991-6_6 · Cited by 9
Lemieux, P., Harvey, J., Guise, T. A., Dallas, M., Oesterreich, S., Yin, J. J., Selander, K. S., & Fuqua, S. A. W. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.9.1570 · Cited by 9
Hypercalcaemia, Parathyroid Hormone-Related Protein and Malignancy
Bayne, M. C., & Illidge, T. (2001) · Clinical Oncology · doi:10.1053/clon.2001.9293 · Cited by 7
Effect of Clodronate on Calcidiol Serum Levels in Women with Breast Cancer
Martı́nez, M., Pastrana, P., Sanchez-Cabezudo, M. J., Jariego, C., & Campo, M. T. D. (1997) · Calcified Tissue International · doi:10.1007/s002239900313 · Cited by 5
Myeloma and other Paraproteinaemias
Robert Souhami CBE, M., & Tobias, J. S. (2005) · Wiley eBooks · doi:10.1002/9780470994887.ch27 · Cited by 4
Myeloma and other paraproteinaemias
Tobias, J. S., & Hochhauser, D. (2014) · Wiley eBooks · doi:10.1002/9781118468753.ch27 · Cited by 2
Formulary Management of Drugs for Cancer-Associated Hypercalcaemia
Gallacher, S. (1996) · PharmacoEconomics · doi:10.2165/00019053-199609010-00005 · Cited by 1
Berenson (2001) · doi:10.1002/1097-0142(20010401)91:7<1191::aid-cncr1119>3.0.co;2-0
Cited by
Writing Committee Members, Levine, G. N., Bates, E. R., Blankenship, J. C., Bailey, S. R., Bittl, J. A., Cercek, B., Chambers, C. E., Ellis, S. G., Guyton, R. A., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31823ba622 · Cited by 3,289
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Circulation · doi:10.1161/cir.0b013e3182776f83 · Cited by 2,410
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
Levine, G. N., Bates, E. R., Blankenship, J. C., Bailey, S. R., Bittl, J. A., Cercek, B., Chambers, C. E., Ellis, S. G., Guyton, R. A., Hollenberg, S. M., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.08.007 · Cited by 2,164
Russell, R. G. G., Watts, N. B., Ebetino, F. H., & Rogers, M. J. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0540-8 · Cited by 1,411
2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery
Hillis, L. D., Smith, P. K., Anderson, J. L., Bittl, J. A., Bridges, C. R., Byrne, J. G., Cigarroa, J. E., DiSesa, V. J., Hiratzka, L. F., Hutter, A. M., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.08.009 · Cited by 820
Metadata
- Authors
- Ross, J., Saunders, Y., Edmonds, P., Patel, S., Wonderling, D., Normand, C., & Broadley, K.
- Venue
- Health Technology Assessment
- Published
- 2004-02
- Volume
- 8
- Issue
- 4
- Pages
- 1-176
- ISSN
- 1366-5278 (ISSN-L)
- 2046-4924
- OpenAlex
- W2152495738
- Cited by
- 467
- References
- 157
- FWCI
- 2.15
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.